Chief Scientific Officer Professor Ludovic Vallier previously established the Cambridge hIPSC Core Facility and Sanger hIPSC platform – generating 100’s lines for the European Stem Cell bank. Our
iPS reprogramming platform is modelled on these high performance facilities. DefiniGEN are a partner in European stem cell bank deriving and validating iPS lines for both pharma and academia. We
use integrative and non-integrative methods to reprogram a range of human blood or fibroblast samples generating hIPSC which are fully QCed.